Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of ALLN-177 in patients with enteric hyperoxaluria.

Clinical Trial Description

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study. This study is designed to determine whether treatment with ALLN-177 for 28 days can reduce urinary oxalate excretion in patients with enteric hyperoxaluria and to evaluate the safety of ALLN-177 in this patient population compared to placebo. ;

Study Design

Related Conditions & MeSH terms

Enteric Hyperoxaluria

Clinical Trial Details

NCT number	NCT03456830
Study type	Interventional
Source	Allena Pharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	May 21, 2018
Completion date	October 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04629170` - Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria	Phase 1
Recruiting	`NCT05650112` - Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria	Phase 1
Recruiting	`NCT05124886` - Gut Kidney Axis in Enteric Hyperoxaluria	N/A
Completed	`NCT05377112` - Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome	Early Phase 1
Terminated	`NCT04909723` - Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects	Phase 1/Phase 2
Completed	`NCT03391804` - Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia	Phase 2
Completed	`NCT00588120` - Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria	Phase 1
Terminated	`NCT03847090` - Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria	Phase 3